株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のウイルス様粒子市場・臨床試験の考察

Global Virus Like Particles Market & Clinical Trial Insight 2023

発行 KuicK Research 商品コード 552681
出版日 ページ情報 英文 180 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界のウイルス様粒子市場・臨床試験の考察 Global Virus Like Particles Market & Clinical Trial Insight 2023
出版日: 2017年09月06日 ページ情報: 英文 180 Pages
概要

当レポートでは、世界のウイルス様粒子市場について調査分析し、市場概要、生産工程、市場分析、臨床パイプライン、上市製品、将来の見通しについて、体系的な情報を提供しています。

第1章 ウイルス様粒子:新世代のワクチン

  • イントロダクション
  • ウイルス様粒子組み立ての要件

第2章 ウイルス様粒子ワクチン開発のウイルス候補

  • ワクチン免疫源としての動物ウイルス様粒子
  • 植物ウイルスベースのウイルス様粒子

第3章 感染症に対するワクチン接種のアプローチとしてのウイルス様粒子の現在の進歩

  • HIV-1ウイルス様粒子
  • C型肝炎ウイルス
  • マラリア
  • ニューカッスル病
  • フィロウイルス
  • ノロウイルス

第4章 ウイルス様粒子ベースワクチンの生産工程

  • 発現系
  • ウイルス様粒子ベースワクチンの下流工程

第5章 ウイルス様粒子ワクチン市場分析

  • イントロダクション
  • ウイルス様粒子ワクチン市場

第6章 世界のウイルス様粒子ワクチンの臨床パイプラインの概要

第7章 世界のウイルス様粒子ワクチン市場力学

  • 好ましいパラメーター
  • 商品化の課題

第8章 ウイルス様粒子ワクチンの将来見通し

第9章 世界のウイルス様粒子ワクチンの臨床パイプライン:企業・適応・相別

  • 研究
  • 前臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相

第10章 上市済みのウイルス様粒子ワクチンの臨床考察

第11章 競合情勢

  • Agilvax
  • Allergy Therapeutics
  • ANGANY Genetics
  • CPL Biologicals
  • Cytos Biotechnology
  • GeoVax Labs
  • GlaxoSmithKline
  • Medicago
  • MedImmune
  • Merck
  • Novavax
  • Serum Institute of India
  • 武田薬品工業
  • TechnoVax
  • Xiamen Innovax Biotech
目次

Vaccination is considered the most cost effective way to control the pathogens and prevent the diseases both in humans and veterinary field. The vaccines based on virus like particles represent one of the most appealing and cost effective approaches due to the intrinsic immunogenic properties as well as high safety profile. The virus like particles also offers several other advantages against the emerging viruses and these are virus like particles are not live viruses and thus manufacturing process offers a safer environment for the operators.

The modern approach for the development of vaccines is focused on the identification of the molecular entities from different organisms as candidates which can mimic the role of viruses. This approach is certainly safer and produces lesser or no side effects after the vaccination process. Virus-like particles are one of such candidates which have shown most promising results and are currently involved in treating a wide range of diseases.

Virus-like particles are composed of the characteristic building proteins of a virus which mimic the properties of the infectious viruses but lack the viral genome. Therefore, Virus like particles became an extremely impressive and promising vaccine candidates due to the presence of virus like but yet non-infective properties in them. Thus, the viruses like particle based vaccines are potentially safer candidates for developing vaccines. Furthermore, Virus like particles are able to induce both innate and adaptive immune responses in humans. Most of the virus like particle based vaccines are derived from the bacteria E.coli as the bacteria E. coli has many advantages, such as inexpensive culturing, high expression levels and easy large scale production. All these advantages of the bacteria will consequentially serve to the development of more cost effective vaccines.

“Global Virus Like Particles Market & Clinical Trial Insight 2023” report highlights:

  • Advances in Virus like Particles as a Vaccination
  • Production Process of Virus like Particle based Vaccines
  • Market Analysis of Virus like Particles Vaccines
  • Global Virus Like Particle Vaccines Clinical Pipeline Insight: 60 Vaccines
  • Marketed Virus Like Particle Vaccines Clinical Insight: 5 Vaccines
  • Future Perspective of Virus like Particles Vaccines

The virus like particle based vaccines is commercially available in market against the hepatitis B virus and human papillomavirus. The viruses like particle based vaccines against several other viruses are in clinical development. The under trial vaccine candidates itself represents the target antigen and those in which the virus like particle is used to present the foreign antigens to immune system. The progresses have been made in developing virus like particle vaccines against hepatitis C virus, Ebola, Lassa virus, Hantavirus and chikungunya virus. Currently there are 60 virus like particle vaccines in clinical trials and 5 virus like particle vaccines are commercially available in the market.

The major pharmaceutical companies have recognized the promising future of the virus like particle vaccines and are widely supporting the manufacturing and production of such vaccines. Major market players include some of the large scale pharmaceutical companies like GlaxoSmithKline's and Merck. The development of the cost effective vaccines are hugely supported by the governmental authorities as well as the academia and pharmaceutical companies.

The future of the virus like particle based vaccines is bright owing to the presence of multiple favorable factors and lesser challenges. The low cost and high efficiency combination will contribute as a robust of the virus like particle vaccines market. Such kind of vaccines will be easily accessible to the consumers due to the expanding market size. The future is even more optimistic in the developing countries where low price will be a favorable parameter for increased customers and demands. Overall the future of the virus like particle based vaccine is very bright and may result in replacing the whole human vaccine market by collecting high revenues for the pharmaceutical industry.

Table of Contents

1. Virus like Particles - New Generation of Vaccines

  • 1.1. Introduction
  • 1.2. Requirements for Virus like Particles Assembly

2. Virus Candidates for Development of Virus like Particle Vaccines

  • 2.1. Animal Virus-like Particles as Vaccine Immunogens
  • 2.2. Plant Virus based Virus like Particles

3. Current Advances in Virus like Particles as a Vaccination Approach against Infectious Diseases

  • 3.1. HIV-1 Virus like Particles
  • 3.2. Hepatitis C Virus
  • 3.3. Malaria
  • 3.4. Newcastle Disease
  • 3.5. Filoviruses
  • 3.6. Norovirus

4. Production Process of Virus like Particle based Vaccines

  • 4.1. Expression Systems
  • 4.2. Downstream Processing of Virus like Particle Based Vaccines

5. Market Analysis of Virus like Particles Vaccines

  • 5.1. Introduction
  • 5.2. Market of Virus like Particle Vaccines

6. Global Virus Like Particle Vaccines Clinical Pipeline Overview

7. Global Virus like Particle Vaccines Market Dynamics

  • 7.1. Favorable Parameters
  • 7.2. Commercialization Challenges

8. Future Perspective of Virus like Particles Vaccines

9. Global Virus Like Particle Vaccines Clinical Pipeline by Company, Indication & Phase

  • 9.1. Research
  • 9.2. Preclinical
  • 9.3. Phase-I
  • 9.4. Phase-I/II
  • 9.5. Phase-II
  • 9.6. Phase-II/III
  • 9.7. Phase-III

10. Marketed Virus Like Particle Vaccines Clinical Insight

  • 10.1. Human papillomavirus vaccine recombinant quadrivalent (Gardasil & Silgard)
  • 10.2. Human papillomavirus vaccine recombinant bivalent (Cervarix)
  • 10.3. Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)
  • 10.4. Influenza Virus Vaccine Trivalent (CadiFlu-S)
  • 10.5. Influenza A Virus H1N1 Vaccine (CadiFlu)

11. Competitive Landscape

  • 11.1. Agilvax
  • 11.2. Allergy Therapeutics
  • 11.3. ANGANY Genetics
  • 11.4. CPL Biologicals
  • 11.5. Cytos Biotechnology
  • 11.6. GeoVax Labs
  • 11.7. GlaxoSmithKline
  • 11.8. Medicago
  • 11.9. MedImmune
  • 11.10. Merck
  • 11.11. Novavax
  • 11.12. Serum Institute of India
  • 11.13. Takeda
  • 11.14. TechnoVax
  • 11.15. Xiamen Innovax Biotech

List of Figures

  • Figure 1-1: Non-Enveloped Virus like Particle Production through Pathogen Component & Fusion to a Vaccine Target Antigen
  • Figure 1-2: Diagram of Enveloped Virus like Particle Production
  • Figure 1-3: Requirements for the Assembly of Virus like Particles
  • Figure 2-1: Types of Plant Virus for Virus like Particles Development
  • Figure 3-1: Modification of HIV-1 Envelope Trimers for Virus like Particle Vaccine
  • Figure 3-2: Virus like Particle Vaccine Strategy against Hepatitis C virus
  • Figure 3-3: New Castle Virus for Virus like Particle Vaccine Development
  • Figure 3-4: Production of Ebola Virus like Particles from Plasmids
  • Figure 4-1: Downstream Process Strategy for Virus like Particle Purification
  • Figure 5-1: Global - Market Growth Potential of Vaccine Industry (US$, Billion), 2017-2023
  • Figure 6-1: Global - Virus Like Particle Vaccines Pipeline by Phase (%), 2017 till 2023
  • Figure 6 2: Global -Virus Like Particle Vaccines Pipeline by Phase (Number), 2017 till 2023
  • Figure 6-3: Global - Virus Like Particle Vaccines Pipeline by Phase (%),2017 till 2023
  • Figure 6-4: Global - Virus Like Particle Vaccines Pipeline by Phase (Number), 2017 till 2023
  • Figure 7-1: Favorable Market Parameters for Vaccine Development
  • Figure 7-2: Challenges to the Market Growth of Vaccines
  • Figure 8-1: Future Scientific Innovations and Challenges for Vaccine Development

List of Tables

  • Table 3-1: Development Status of Virus like Particle Vaccine Candidates
  • Table 4-1: Properties of Various Expression Systems for Production of Virus like Particle
Back to Top